52 results on '"Dammacco, F"'
Search Results
2. Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera
- Author
-
Landolfi, R, Marchioli, R, Kutti, J, Gisslinger, H, Tognoni, G, Patrono, C, Barbui, T, Finazzi, G, Pusterla, S, Falanga, A, Galli, M, Wadenvik, H, Gastl, G, Ludescher, C, Lutz, D, Girschikofsky, M, Michlmayr, G, Rechberger, E, Niessner, H, Ivansich, E, Rain, Jd, Chommienne Thomas, C, Hehlmann, R, Engelich, G, Kohne, E, Kramer, A, Christakis, Ji, Papaioannou, M, Gerotziafas, G, O'Donnell, R, Bennett, M, Lugassy, G, Ellis, M, Eldor, A, Naparstek, E, Marilus, R, Leoni, P, Rupoli, S, Scortechini, Ar, Agostini, V, Volpe, E, Calmieri, F, Volpe, A, Storti, G, Ciampa, A, Dammacco, F, Lauta, Vm, Ranieri, G, Rizzi, R, Orsola, S, Tura, S, Finelli, C, Marino, G, Rossi, G, Almici, C, Capucci, A, Zanetti, F, Giustolisi, R, Cacciola, Rr, Cacciola, E, Peta, A, Magro, D, Frigerio, G, Alberio, F, Beretta, A, Bonferroni, M, Raviolo, A, Ferrini, Prl, Grossi, A, Fabbri, A, Nardelli, S, Centra, A, Musolino, C, Bellomo, G, Trincali, O, Spatari, Giovanna, Foa, P, Gerli, G, Carraro, Mc, Zanella, A, Lurlo, A, Barraco, F, Torelli, G, Marietta, M, Pogliani, E, Miccolis, Ir, La Rocca, A, Puglisi, A, Sardeo, G, Rotoli, B, Martinelli, V, Ciancia, R, Cardarelli, A, Cimino, R, Fasanaro, A, Randi, Ml, Rizzoli, V, Caramatti, C, Gaeta, L, Lazzarino, M, Passamonti, F, Lazzola, M, Malabarba, L, Natale, D, Pulini, S, Davi, G, Gugliotta, L, Ilariucci, F, De Candia, E, Eugenio, S, Amadori, S, Buccisano, F, Mandelli, F, Montefusco, E, Petti, Mc, Spadea, A, Carotenuto, M, Morelli, A, Nobile, M, Longinotti, M, Pardini, Sm, Lauria, F, Buccalossi, A, Gentili, S, Mazza, P, Cervellera, M, Maggi, A, Di Francesco, A, Pasqualoni, E, Chisesi, T, Polacco, A, Capnist, G, Rodeghiero, F, Ruggeri, M, Arrizabalaga, B, Remacha, A, De Mendiguren, Bp, Hernandez Nieto, L, Hernandez Garcia, Mt, Gonzalez Brito, G, Machado, P, Garcia, G, Villegas, A, Pena, A, Fernandez, Ag, Carbonell, F, Del Arco, A, Back, H, Stenke, L, Hansen, S, Larsson, G, Stromblad, G, Lauri, B, Ryden, Bo, Linder, O, Lundholm, Bg, Lannemyr, O, Strandberg, M, Andreasson, B, Stockelberg, D, Pasquariello, F, Tichelli, A, Otremba, B, Hinrichs, Hf, Weber Stadelmann, W, Bareford, D, Oscier, Dg, Bowey, N, Taylor, Pc, de Gaetano, G, Najean, Y, Pearson, Tc, Di Blasio, A, Atashkar, S, Mari, E, Tamayo, D, Borelli, G, Ferri, B, Marfisi, Rm, Olivieri, M, Polidoro, A, Spoltore, R, Levantesi, G, Di Mascio, R, Miceli, G, Sperti, G, Correale, E, Vermjlen, J, and Collins, R.
- Subjects
Aspirin ,medicine.medical_specialty ,business.industry ,food and beverages ,General Medicine ,medicine.disease ,Thrombosis ,Pulmonary embolism ,Venous thrombosis ,Polycythemia vera ,Relative risk ,Internal medicine ,Anesthesia ,Cardiology ,Medicine ,Myocardial infarction ,business ,Contraindication ,medicine.drug - Abstract
background The use of aspirin for the prevention of thrombotic complications in polycythemia vera is controversial. methods We enrolled 518 patients with polycythemia vera, no clear indication for aspirin treatment, and no contraindication to such treatment in a double-blind, placebo-controlled, randomized trial to assess the safety and efficacy of prophylaxis with low-dose aspirin (100 mg daily). The two primary end points were the cumulative rate of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes and the cumulative rate of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes. The mean duration of follow-up was about three years. results Treatment with aspirin, as compared with placebo, reduced the risk of the combined end point of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes (relative risk, 0.41; 95 percent confidence interval, 0.15 to 1.15; P=0.09) and the risk of the combined end point of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes (relative risk, 0.40; 95 percent confidence interval, 0.18 to 0.91; P=0.03). Overall mortality and cardiovascular mortality were not reduced significantly. The incidence of major bleeding episodes was not significantly increased in the aspirin group (relative risk, 1.62; 95 percent confidence interval, 0.27 to 9.71). conclusions Low-dose aspirin can safely prevent thrombotic complications in patients with polycythemia vera who have no contraindications to such treatment.
- Published
- 2004
3. Human Erythropoietin Induces a Pro-Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo
- Author
-
Ribatti, D., Presta, M., Vacca, A., Roberto Ria, Giuliani, R., Era, P., Nico, B., Roncali, L., and Dammacco, F.
- Subjects
Umbilical Veins ,Immunology ,Neovascularization, Physiologic ,Chick Embryo ,Biochemistry ,Cell Fusion ,Allantois ,Proto-Oncogene Proteins ,Tumor Cells, Cultured ,Animals ,Humans ,Endothelium ,Phosphorylation ,Erythropoietin ,Cells, Cultured ,Neovascularization ,Dose-Response Relationship, Drug ,Metalloendopeptidases ,Chorion ,Cell Biology ,Hematology ,Janus Kinase 2 ,Protein-Tyrosine Kinases ,Recombinant Proteins ,Kinetics ,Gelatinases ,Matrix Metalloproteinase 2 ,Endothelium, Vascular ,Cell Division - Abstract
Hematopoietic and endothelial cell lineages share common progenitors. Accordingly, cytokines formerly thought to be specific for the hematopoietic system have been shown to affect several functions in endothelial cells, including angiogenesis. In this study, we investigated the angiogenic potential of erythropoietin (Epo), the main hormone regulating proliferation, differentiation, and survival of erythroid cells. Epo receptors (EpoRs) have been identified in the human EA.hy926 endothelial cell line by Western blot analysis. Also, recombinant human Epo (rHuEpo) stimulates Janus Kinase-2 (JAK-2) phosphorylation, cell proliferation, and matrix metalloproteinase-2 (MMP-2) production in EA.hy926 cells and significantly enhances their differentiation into vascular structures when seeded on Matrigel. In vivo, rHuEpo induces a potent angiogenic response in the chick embryo chorioallantoic membrane (CAM). Accordingly, endothelial cells of the CAM vasculature express EpoRs, as shown by immunostaining with an anti-EpoR antibody. The angiogenic response of CAM blood vessels to rHuEpo was comparable to that elicited by the prototypic angiogenic cytokine basic fibroblast growth factor (FGF2), it occurred in the absence of a significant mononuclear cell infiltrate, and it was not mimicked by endothelin-1 (ET-1) treatment. Taken together, these data demonstrate the ability of Epo to interact directly with endothelial cells and to elicit an angiogenic response in vitro and in vivo and thus act as a bona fide direct angiogenic factor.
- Published
- 1999
4. Angiogenic activity of rat mast cells in the chick embryo chorioallantoic membrane is down-regulated by treatment with recombinant human alfa-2a interferon and partly mediated by fibroblast growth factor 2
- Author
-
RIBATTI D, CRIVELLATO E, VACCA A, NICO B, BENAGIANO V, RONCALI L, DAMMACCO F., CANDUSSIO, LUIGI, Ribatti, D, Crivellato, E, Candussio, Luigi, Vacca, A, Nico, B, Benagiano, V, Roncali, L, and Dammacco, F.
- Published
- 2002
5. Mast cells and their secretory granules are angiogenic in the chick embryo chorioallantoic membrane
- Author
-
Ribatti, D., Crivellato, Enrico, Candussio, L., Nico, B., Vacca, A., Roncali, L., Dammacco, F., Ribatti, D, Crivellato, E, Candussio, Luigi, Nico, B, Vacca, A, Roncali, L, and Dammacco, F.
- Published
- 2001
6. Problems of Hypoglycemia arising in Children and Adolescent with Insulin Dependent Diabetes Mellitus
- Author
-
Dammacco F, Torelli C, Frezza E, in the Collaborative Pediatric Diabetologic G.r.o.u.p., FRANZESE, ADRIANA, Dammacco, F, Torelli, C, Frezza, E, Franzese, Adriana, and in the Collaborative Pediatric Diabetologic, G. r. o. u. p.
- Published
- 1998
7. p16 gene analysis in multiple myeloma (MM)
- Author
-
Gernone A, Pietrafesa A, Dammacco F., IOLASCON, ACHILLE, Gernone, A, Iolascon, Achille, Pietrafesa, A, and Dammacco, F.
- Subjects
Base Sequence ,Bone Marrow ,Molecular Sequence Data ,Paraproteinemias ,Humans ,Genes, Tumor Suppressor ,Exons ,Carrier Proteins ,Multiple Myeloma ,Polymerase Chain Reaction ,Cyclin-Dependent Kinase Inhibitor p16 ,Gene Deletion ,DNA Primers - Published
- 1996
8. Mast cell heterogeneity in B-cell non-Hodgkin's lymphoma. An ultrastructural study
- Author
-
Crivellato, Enrico, Dammacco, F, Nico, B, Ribatti, D, and Vacca, A.
- Published
- 2002
9. RISK FOR THE DEVELOPMENT OF TYPE I DIABETES IN CHILDREN WITH INCIDENTAL HYPERGLYCEMIA (MULTICENTER ITALIAN STUDY) DIABETES CARE
- Author
-
Lorini, L., Alibrandi, A., Vitali, L., Martinetti, M., Betterle, C., D'Annunzio, G., Cherubini, E. BONIFACIO AND PEDIATRIC ITALIAN STUDY GROUP OF PREDIABETES V., Cavallo, L., Dammacco, F., Cerasoli, G., Pocecco, M., Tumini, S., Chiarelli, F., Mancuso, M., Banin, P., Toni, S., Martinucci, M., Barella, C., Coltellessa, M., Monaci, A., Lombardo, F., Meschi, F., Chiumello, G., Iughetti, L., Brnasconi, S., Iafusco, D., Prisco, F., Franzese, A., Cadario, F., Cardella, F., Monciotti, C., Giacchero, R., Avanzini, M. A., Calisti, M. A. L., Chiari, G., Vanelli, M., Guazzarotti, L., Sulli, Nicoletta, Multari, G., Crin, A., Marietti, G., Piccinini, S., MANCA BITTI, L. M., Sacchini, P., Masciani, A., Sacchetti, C., Cerutti, F., Tonini, G., Visentin, A., Contreas, G., and Pinelli, L.
- Published
- 2001
10. [Angiogenesis and tumor progression in melanoma]
- Author
-
Vacca A, Roberto Ria, Ribatti D, Bruno M, and Dammacco F
- Subjects
Vascular Endothelial Growth Factor A ,Lymphokines ,Neovascularization, Pathologic ,Hepatocyte Growth Factor ,Vascular Endothelial Growth Factors ,Endothelial Growth Factors ,Neoplasm Proteins ,Receptors, Laminin ,Cell Transformation, Neoplastic ,Transforming Growth Factor beta ,Disease Progression ,Humans ,Fibroblast Growth Factor 2 ,Neoplasm Invasiveness ,Melanoma ,Cell Division - Abstract
Angiogenesis is defined as the formation of new blood capillaries from preexisting vessels. It takes place in physiological and pathological conditions, such as cancer. Tumor angiogenesis depends on the release of angiogenic growth factors by tumor cells and infiltrating inflammatory cells, and from the extracellular matrix following degradation by tumor proteases. Human melanoma progresses through different steps: nevocellular nevi, dysplastic nevi, in situ melanoma, radial growth phase melanoma (Breslow indexor = 0.75 mm), vertical growth phase melanoma (Breslow index0.75 mm), and metastatic melanoma. In agreement with progression, it acquires a rich vascular network, whereas an increasing proportion of tumor cells express the laminin receptor, which enables their adhesion to the vascular wall. Hence, both phenomena favour tumour cell extravasation and metastases. Melanocytic cells produce and release Fibroblast Growth Factor-2 (FGF-2), mainly in the steps of dysplastic nevus and melanoma in vertical growth phase. Melanoma cells also secrete the Vascular Endothelial Growth Factor (VEGF), in parallel with the switch from the radial to the vertical growth phase and the metastatic phase. It is becoming clear that anti-angiogenic agents will interfere with or block melanoma progression.
- Published
- 2000
11. Nef protein induces differential effects in CD8+ cells from HIV-1-infected patients
- Author
-
Silvestris, F, Camarda, G, DEL PRETE, Annalisa, Tucci, M, and Dammacco, F.
- Subjects
CD4-Positive T-Lymphocytes ,virus diseases ,Apoptosis ,HIV Infections ,3T3 Cells ,CD8-Positive T-Lymphocytes ,Lymphocyte Activation ,Transfection ,Coculture Techniques ,Gene Products, nef ,Lymphocyte Depletion ,Recombinant Proteins ,Immunophenotyping ,Mice ,Reference Values ,HIV-1 ,Animals ,Humans ,nef Gene Products, Human Immunodeficiency Virus ,Cells, Cultured - Abstract
The Nef protein of HIV-1 is suspected to play a role in the depletion of uninfected CD4+ lymphocytes that leads to AIDS. By contrast its effect on CD8+ cells, whose functions are also deregulated during HIV-1 infection, is presently unclear. Here we describe a number of derangements induced in vitro by Nef in CD8+ cells from HIV-1-infected patients.Peripheral lymphocytes from 16 HIV-1+ subjects and 9 uninfected individuals were cultivated on a Nef-transfected mouse fibroblast layer exposing the carboxyl-terminal region of the viral protein on cell membrane. The cultures were then measured for both apoptosis and proliferation by subdiploid DNA content and Ki67 expression, respectively, whereas the molecular analysis of purified CD8+ cells investigated the Fas-L mRNA levels in Nef-treated CTLs. In addition, we evaluated the Nef-induced variation in the extent of CD8+/HLA-DR+ subset, which includes non cytotoxic cells secreting T-cell antiviral factor (CAF) and a soluble factor inhibiting the HIV-1 replication.The viral protein induced in peripheral blood lymphocytes (PBL) a moderate tendency to proliferate, as measured by the increment of Ki67 antigen, particularly on the CD8+ subset of HIV-1 infected individuals (P0.05). This profile was particularly evident in cultures from patients with severe CD4+ lymphopenia and paralleled an apparent expansion of the CD8+/CD57+ suppressor cell subset. Molecular analysis of purified CD8+ cells revealed a defective expression of Fas-L mRNA in Nef-cultured CTLs, whereas the viral protein exerted a down modulatory effect on the CD8+/HLA-DR+ subset (P0.05), thus suggesting a potential inhibition of CAF.These results support a potential role of Nef in the progression of HIV-1 infection as a number of cellular functions are affected in the CD8+ subset. In particular, the defective functions of CD8+ cells induced by the viral protein could contribute, at least partly, to the escape of HIV-1 from the immune control of these cells.
- Published
- 1999
12. Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia
- Author
-
Domenico Ettore SANSONNO, Vita, S., Iacobelli, A. R., Cornacchiulo, V., Boiocchi, M., and Dammacco, F.
- Subjects
Adult ,Male ,B-Lymphocytes ,Immunology ,Hepacivirus ,Sequence Analysis, DNA ,Hepatitis C, Chronic ,Middle Aged ,Clone Cells ,Cryoglobulinemia ,Liver ,Rheumatoid Factor ,Immunology and Allergy ,Humans ,RNA, Viral ,Female ,Gene Rearrangement, B-Lymphocyte ,In Situ Hybridization ,Aged - Abstract
Clonal rearrangements of Ig heavy chain (IgH) genes and hepatitis C virus (HCV) genomic sequences were assayed on intrahepatic B lymphocytes isolated from HCV chronically infected patients with and without type II mixed cryoglobulinemia (MC). Liver tissue samples from eight patients with and nine without MC were subjected to routine histologic studies, immunophenotyping, and genotypic analysis including IgH V-D-J region gene rearrangements by PCR. RT-PCR, signal amplification by branched DNA assay, and in situ hybridization technique were used to detect and quantitate HCV RNA genomic sequences in selected B cells purified from each tissue sample. Although HCV infection of intrahepatic B cells was shown in all patients both with and without MC, frank B cell monoclonal and oligoclonal patterns were found in only three and four patients with MC, respectively. No monoclonal profile was seen in the noncryoglobulinemic patients, whereas an oligoclonal profile was demonstrated in four of them. No clonalities were shown in HCV-unrelated patients matched for age and severity of liver disease. No obvious difference in HCV genotype distribution was found in relation to the clonal expansion profile. Noncryoglobulinemic patients showing clonal expansion in liver tissue had higher titers of serum rheumatoid factor (RF). Spontaneous production of RF was shown in cell cultures of intrahepatic B cells, suggesting their persistent stimulation in vivo. These data indicate that HCV infection of B cells and B cell clonal expansions occur in the liver microenvironment and preferentially involve RF-producing cells.
- Published
- 1998
13. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients
- Author
-
Boccadoro, M., Marmont, F., Tribalto, M., Awisati, G., Andriani, A., Barbui, T., Maria CANTONETTI, Carotenuto, M., Comotti, B., Dammacco, F., Frieri, R., Gallamini, A., Gallone, G., Giovangrossi, P., Grignani, F., Lauta, V. M., Liberati, M., Musto, P., Neretto, G., Petrucci, M. T., Resegotti, L., Pilerl, A., and Mandelli, F.
- Subjects
Melphalan ,Male ,Cancer Research ,Settore MED/06 - Oncologia Medica ,vincristine EMTREE medical terms: article ,THERAPY ,Middle Age ,priority journal MeSH:Aged ,Prednisone ,Antineoplastic Combined Chemotherapy Protocols ,Non-U.S. Gov't ,combination chemotherapy ,Combination chemotherapy ,Middle Aged ,Prognosis ,intravenous drug administration ,Oncology ,Vincristine ,SURVIVAL ,Female ,Support ,Multiple Myeloma ,medicine.drug ,medicine.medical_specialty ,Cyclophosphamide ,Urology ,Drug Administration Schedule ,medicine ,Humans ,Comparative Study ,human ,KINETICS ,Aged ,Carmustine ,VINCRISTINE ,business.industry ,Induction chemotherapy ,EMTREE drug terms:beta 2 microglobulin ,major clinical study ,Surgery ,carmustine ,cyclophosphamide ,doxorubicin ,melphalan ,prednisone ,female ,male ,multiple myeloma ,beta 2-Microglobulin ,Doxorubicin ,Human ,Support, Non-U.S. Gov't ,Regimen ,business ,Settore MED/15 - Malattie del Sangue - Abstract
The efficacy of alternating vincristine, melphalan (M), cyclophosphamide, prednisone/vincristine, carmustine, doxorubicin, and prednisone (VMCP/VBAP) polychemotherapy was compared with the M and prednisone (MP) regimen as induction treatment in multiple myeloma (MM). Three hundred four MM patients entered this study between March 1983 and July 1986; the analysis was performed in December 1989. The treatment groups did not show significant differences with respect to major prognostic factors. Median overall survival was 33.8 months. In the VMCP/VBAP and MP arms, after 12 induction chemotherapy cycles, 59.0% and 47.3% (P less than .068) of the patients achieved an M component reduction greater than 50%. No significant difference was observed in the two treatment arms in terms of remission duration (21.3 v 19.6 months, P less than .66) and survival (31.6 v 37.0 months, P less than .28). Patients younger than 65 years did not show any advantage from the alternating polychemotherapy. At diagnosis, the plasma cell labeling index (LI) and serum beta-2 microglobulin (beta 2-m) were evaluated in 173 and 183 patients, respectively. A significantly reduced survival was observed for patients with LI greater than or equal to 2% (16.4 months) or beta 2-m greater than or equal to 6 mg/L (20.4 months). Even in these poor-risk subgroups, VMCP/VBAP was not superior to MP.
- Published
- 1991
14. MACOP-B vs F-MACHOP in the treatment of high-grade non-Hodgkin's lymphomas
- Author
-
Tura, S., Mandelli, F., Mazza, P., Pileri, S., Gherlinzoni, F., Bocchia, M., Zinzani, P. L., Fiacchini, M., Martelli, M., Papa, G., Antimi, M., Martelli, M. F., Grignani, F., Brunangelo FALINI, Calabresi, F., Ruggeri, E. M., Dammacco, F., Lauta, V. M., Lucarelli, G., and Moretti, L.
- Subjects
Adult ,Male ,Lymphoma ,Lymphoma, Non-Hodgkin ,Prednisolone ,Cytarabine ,High-Grade ,Adult, Antineoplastic Combined Chemotherapy Protocols, Bleomycin, Bone Marrow, Comparative Study, Cyclophosphamide, Cytarabine, Doxorubicin, Drug Administration Schedule, Female, Fluorouracil, Human, Lymphoma ,High-Grade, Male, Methotrexate, Prednisolone, Prednisone, Survival Analysis, Vincristine ,Survival Analysis ,Drug Administration Schedule ,Bleomycin ,Methotrexate ,Bone Marrow ,Doxorubicin ,Vincristine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Prednisone ,Comparative Study ,Female ,Fluorouracil ,Cyclophosphamide ,Human - Abstract
From September 1988 two hundred-sixty-seven (267) untreated patients (pts) with stage II to IV high grade non Hodgkin's lymphoma (NHL) have been enrolled in a multicenter, randomized, still ongoing study, comparing two third-generation combination chemotherapy regimens, MACOP-B versus F-MACHOP. At the present time, 177 pts have completed the treatment program and are evaluable, with a median follow-up of 13 months. Clinical, histologic and laboratory characteristics are equally distributed in both groups. Among the 92 pts treated with MACOP-B, 58 (63%) achieved a complete remission (CR), 17 complete responders have relapsed (29%), and 21 have died (23%), including 3 treatment-related deaths. Among the 85 pts who received F-MACHOP, 65 (76%) achieved a CR, 9 complete responders have relapsed (14%), and 11 pts have died (13%), including 3 treatment related deaths. 30 months-projected survival is 64% for MACOP-B treated pts compared to 84% for F-MACHOP treated pts; 30 months-projected relapse- free survival is 80% and 84%, respectively. F-MACHOP seems to be superior in immunoblastic lymphoma (overall survival, OS, 82% vs. 54%) and in Burkitt-type lymphoblastic lymphoma (OS 100% vs, 42%). The degree of hematological and non-hematological toxicity was similar in both regimens. More reliable conclusions will be drawn after a longer follow-up.
- Published
- 1991
15. Abdominal lymphoma and alpha chain disease
- Author
-
R. Marano, Dammacco F, G.M. Bonomo, and Lorenzo Bonomo
- Subjects
Pathology ,medicine.medical_specialty ,Saliva ,Malabsorption ,medicine.diagnostic_test ,business.industry ,Albumin ,General Medicine ,Immunoelectrophoresis ,Immunoglobulin light chain ,medicine.disease ,Lymphoma ,medicine.anatomical_structure ,Biopsy ,medicine ,Mesenteric lymph nodes ,business - Abstract
Clinical, pathologic and immunocytochemical studies were performed in three patients with α-chain disease. All three patients were female, aged twenty-one, forty-four and twenty-three years, respectively. Malabsorption, diarrhea, abdominal pain and progressive general deterioration were the main clinical features; the liver and spleen were normal or only slightly enlarged, and the skeleton appeared roentgenologically unaffected. Biopsy and/or autopsy evidence was obtained of a malignant lymphoma extensively involving the small intestine and the mesenteric lymph nodes. The histopathologic picture consisted of a dense cellular infiltration which was pleomorphic although composed mainly of plasma cells. The serum electrophoretic pattern showed an abnormal band in one patient and only minor changes in the other two. A peculiar protein, immunologically related to the heavy polypeptide chains of IgA but devoid of light chains, was detected by immunoelectrophoresis in serum and concentrated urine samples; trace amounts were also detected in the saliva but not in the tears of one patient. It was also demonstrated in the cell extract of a culture of an intestinal biopsy specimen. The peculiar IgA was antigenically deficient as compared with some IgA myeloma proteins and sedimented more slowly in the ultracentrifuge than both IgA myeloma protein and albumin. In addition it showed striking electrophoretic heterogeneity, a tendency to form polymers and belonged to the α 1 , subclass in all three cases. All three patients were from the south of Italy, and in none of them could an Arab or Jewish ancestry be definitely established.
- Published
- 1972
16. [Adenosine deaminase and nucleoside phosphorylase: a new approach to the etiopathogenesis of various immunologic deficiencies]
- Author
-
LUCIVERO, Giacomo, DAMMACCO F, BONOMO L., Lucivero, Giacomo, Dammacco, F, and Bonomo, L.
- Subjects
Erythrocytes ,Purine-Nucleoside Phosphorylase ,Adenosine Deaminase ,Electrophoresis, Starch Gel ,Immunologic Deficiency Syndromes ,Humans ,Lymphocytes ,Nucleoside Deaminases ,Pentosyltransferases - Published
- 1977
17. ARGOMENTI DI IMMUNOLOGIA CLINICA
- Author
-
ANTONACI S, PALAZZO MG, DAMMACCO F., LUCIVERO, Giacomo, Antonaci, S, Palazzo, Mg, Lucivero, Giacomo, and Dammacco, F.
- Published
- 1976
18. Letter: Polycystic renal disease, hypertension, and IgA deficiency
- Author
-
DAMMACCO F, BONOMO L., LUCIVERO, Giacomo, Dammacco, F, Lucivero, Giacomo, and Bonomo, L.
- Subjects
Adult ,Male ,Polycystic Kidney Diseases ,Hypertension ,Immunoglobulin A, Secretory ,Immunologic Deficiency Syndromes ,Humans ,Dysgammaglobulinemia ,Immunoglobulin A - Published
- 1976
19. THYROGLOBULIN ANTIBODIES IN LEPROSY
- Author
-
Pinto L, Dammacco F, G. Barbieri, and Bonomo L
- Subjects
biology ,business.industry ,medicine.medical_treatment ,Autoantibody ,General Medicine ,medicine.disease ,Thyroglobulin ,Antibodies ,Autoimmune Diseases ,Serology ,Rheumatoid Factor ,Leprosy ,Immunology ,biology.protein ,Humans ,Rheumatoid factor ,Medicine ,Serologic Tests ,Antibody ,business ,Autoantibodies - Published
- 1963
20. Effects of 2-bromo-alpha-ergocryptine and pimozide on growth hormone secretion in man
- Author
-
G. Chetri, F. Gagliardi, Rigillo N, A. Dammacco, E. Tafaro, and Dammacco F
- Subjects
Adult ,medicine.medical_specialty ,2-Bromo-alpha-ergocryptine ,Time Factors ,Adolescent ,Chemistry ,Endocrinology, Diabetes and Metabolism ,Biochemistry (medical) ,Clinical Biochemistry ,Pimozide ,General Medicine ,Biochemistry ,Growth hormone secretion ,Menstruation ,Endocrinology ,Internal medicine ,Growth Hormone ,medicine ,Humans ,Female ,Ergolines ,Bromocriptine ,medicine.drug - Published
- 1976
21. L.E. CELLS AND ANTINUCLEAR FACTORS IN LEPROSY
- Author
-
Dammacco F, Bonomo L, Tursi A, and Trimigliozzi G
- Subjects
Lepromatous leprosy ,business.industry ,Neutrophils ,General Engineering ,Autoantibody ,Fluorescent Antibody Technique ,General Medicine ,Papers and Originals ,medicine.disease ,Autoimmune Diseases ,Antibodies, Antinuclear ,Leprosy ,Immunology ,medicine ,General Earth and Planetary Sciences ,Humans ,business ,General Environmental Science ,Autoantibodies - Published
- 1965
22. [The advent of biosimilars: new rules to guarantee patient safety]
- Author
-
Gesualdo L, Mp, Abbracchio, Dammacco F, Goffredo F, Zanella A, and Claudio Ronco
- Subjects
Biological Products ,Humans ,Safety - Abstract
Biosimilars are medicinal products proposed as copies of biotech drugs whose patents have expired. Their entry into the therapeutic armamentarium entails knowledge of the rules established in Europe relevant to their use in clinical practice. In September 2007, an Italian panel of experts comprising two nephrologists, a clinical immunologist, an oncohematologist, a pharmacologist, and a hospital pharmacist examined the main features of biotech drugs and the issues faced by the regulatory authorities in the definition of a specific approval pathway for biosimilars in Europe. The panel of experts agreed that it is important to inform the medical and scientific community that biosimilars are not exact copies of their reference products; therefore the rules governing their clinical use are not the same as those established for biotech drugs in general. Patient safety should be the fundamental principle guiding therapeutic choices, and making these choices should be the prerogative of physicians.
23. Cell kinetics and therapy in multiple myeloma: An uptake of the M83 protocol
- Author
-
Pileri, A., Barbui, T., Mario Boccadoro, Comotti, B., Dammacco, F., Gallamini, A., Marmont, F., Neretto, G., Petrucci, M. T., Resegott, L., Tribalto, M., and Mandelli, F.
24. Natural interferon-α versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: A long-term, randomized, controlled study
- Author
-
Dammacco, F., Sansonno, D., Han, J. H., Shyamala, V., Cornacchiulo, V., Iacobelli, A. R., Lauletta, G., and Rita Rizzi
25. Mesenchymal stem cells and bone regeneration,Cellule staminali mesenchimali e medicina rigenerativa dell'osso
- Author
-
Ciavarella, S., Matteo, M., Paola Cafforio, Dammacco, F., and Silvestris, F.
26. αvβ3 integrin engagement enhances cell invasiveness in human multiple myeloma
- Author
-
Roberto Ria, Vacca, A., Ribatti, D., Di Raimondo, F., Merchionne, F., and Dammacco, F.
27. Antiphosphatidylserine antibodies in human immunodeficiency virus-1+ patients correlate with evidence of T-cell apoptosis and mediate antibody-dependent cellular cytotoxicity
- Author
-
Silvestris, F., Frassanito, M. A., Cafforio, P., Potenza, D., Di Loreto, M., Marco Gaetano Tucci, Grizzuti, M. A., Nico, B., and Dammacco, F.
28. Anti-CD4 monoclonal antibody (mAb) and anti-idiotypic mAb to anti-CD4 in the therapy of autoimmune diseases
- Author
-
Federico Perosa, Scudeletti, M., Imro, M. A., Dammacco, F., Luccarelli, G., and Indiveri, F.
29. Hepatitis C virus infection and clonal B-cell expansion
- Author
-
Sansonno, D., Cornacchiulo, V., Iacobelli, A. R., Pietro Gatti, Distasi, M., and Dammacco, F.
30. The Registry for Insulin-Dependent Diabetes Mellitus in Italy (RIDI) project,Il progetto per il registro italiano del Diabete Mellito insulino-dipendente (RIDI)
- Author
-
Cherubini, V., Carle, F., Iannilli, A., Kantar, A., Coppa, G. V., Chiumello, G., Angius, E., Banin, P., Bellù, L., Berardi, R., Bernasconi, S., Mariani, S., Boscherini, B., Fonte, M. T., Cacciari, E., Salardi, S., Cadario, F., Calisti, francesca cardella, Cavallo, L., Cerasoli, G., Cerutti, F., Chiarelli, F., Verrotti, A., Cicchetti, M., Cotellessa, M., Picco, P., Crino, A., Dammacco, F., Giorgi, G., Luca, F., Falorni, A., Fifi, A., Franzese, A., Gargantini, G., Giorgetti, R., Guazzarotti, L., La Loggia, A., Lorini, R., D Annunzio, G., Lucentini, L., Mannazzu, M. C., Marietti, G., Marsciani, A., Martinucci, M., Mastrangelo, C., Meossi, C., Meschi, F., Monciotti, C., Multari, G., Pinelli, L., Pocecco, M., Prisco, F., Jafusco, D., Reitano, G., Sacchini, P., Sacco, M., Salvatoni, A., Scaramuzza, A., Vanelli, M., Chiari, G., Vanini, R., Visentin, A., and Zanini, R.
31. Upregulation of erythroblast apoptosis by malignant plasma cells: A new pathogenetic mechanism of anemia in multiple myeloma
- Author
-
Silvestris, F., Paola Cafforio, Grinello, D., and Dammacco, F.
32. Differential expression of ICAM-1 and LFA-1 in B-cell non-Hodgkin lymphoma,ESPRESSIONE DIFFERENZIALE DI ICAM-1 E LFA-1 NEI LINFOMI NON-HODGKIN A CELLULE B
- Author
-
Girolamo Ranieri, Vacca, A., Di Reda, D., Gadaleta-Caldarola, G., Franco, G., Caloro, D., and Dammacco, F.
33. Primary intimal sarcoma of the thoracic aorta
- Author
-
Tucci, M., Quatraro, C., Calvani, N., gabriella serio, Marzullo, A., Dammacco, F., and Silvestris, F.
- Subjects
Radiography ,Tomography Scanners, X-Ray Computed ,Humans ,Aorta, Thoracic ,Female ,Sarcoma ,Middle Aged - Abstract
Primary aortic tumors are well known for both their rarity and variability in clinical presentation and usually are diagnosized post-operatively or by post-mortem examination. Intimal sarcoma is a recurrent histological variant and the involvement of the thoracic aorta is an unusual presentation. Angiography and computed tomography are accurate methods to evaluate aortic tumors though transesophageal echocardiography is actually used for the differential diagnosis. Here, we describe an unusual intimal sarcoma of the thoracic aorta whose clinical feature strongly mimicked a diffuse thrombotic disease.
34. I primi 4 anni di screening del prediabete in Italia
- Author
-
Lorini, R., Angius, E., Arrigo, T., Banin, P., Bartolotta, E., Cadario, F., Calisti, L., francesca cardella, Cerasoli, G., Cerutti, F., Cherubini, V., Chiarelli, F., Cotellessa, M., Dammacco, F., Giorgi, G., Falorni, A., Fonte, M. T., Franzese, A., Gallo, F., Iafusco, D., Marietti, G., Marsciani, A., Martinucci, M., Meschi, F., Monciotti, C., Multari, G., Picco, P., Pinelli, L., Pocecco, M., Sacchini, P., Salardi, S., Vanelli, M., and Vitali, L.
35. Serum elevations of soluble Fas (CD95/Apo-I) concur in deregulating T cell apoptosis during active lupus disease
- Author
-
Francesco Silvestris, Williams, R. C., Calvani, N., Grinello, D., Tucci, M., Cafforio, P., and Dammacco, F.
36. Human CD4-internal antigen anti-idiotypic monoclonal antibody: Induction of a CD4-specific response in humans
- Author
-
Federico Perosa, Scudeletti, M., Imro, M. A., Dammacco, F., and Indiveri, F.
- Subjects
Immunology ,Immunology and Allergy - Abstract
We previously showed that anti-idiotypic mAb (mAb2) F16-16D7 (16D7) to the paratope (or paratope-related idiotope) of the anti-CD4 mAb HP2/6 induces anti-CD4 Abs in BALB/c mice. In view of the potential ability of 16D7 to induce anti-CD4 Ab in humans and the potential benefits of anti-CD4 Abs in the treatment of autoimmune diseases, we evaluated the immunologic response to and assessed the safety of four 2-mg 16D7 s.c. injections in one patient with systemic lupus erythematosus (SLE) and one with rheumatoid arthritis (RA). 16D7 induced anti-isotypic and anti-anti-idiotypic Abs (Ab3), which were almost exclusively of the IgG isotype. Ab3 specifically reacted with 16D7 as they inhibited its binding to mAb HP2/6. Although Ab3 did not react with cellular or recombinant CD4 (rCD4), single-cell enzyme-linked immunospot assays of anti-CD4 Ab production revealed many more spot-forming cells in rCD4- and 16D7-coated wells than in wells coated with BSA or 16D7 isotype-matched MK2-23. Spot-forming anti-CD4 Abs were specifically induced by 16D7, since rCD4-dependent spot formation 1) was not observed with PBL from one patient with SLE, one with mixed connective tissue disease, and one with melanoma immunized with MK2-23; and 2) was inhibited by 16D7 and not by MK2-23. Spot-forming anti-CD4 Abs recognize a CD4 epitope identical (or closely related) to that seen by HP2/6, since this specifically inhibited spot formation. A substantial, although transient, CD4+ T cell depletion was only observed in the RA patient. Local and/or general toxicity and laboratory and/or clinical signs indicative of immunodepression or diseases relapse were not observed during an 18-month follow-up.
37. Immunologic effects of long-term thymopentin treatment in patients with HIV-induced lympadenopathy syndrome
- Author
-
Francesco Silvestris, Gernone, A., Frassanito, M. A., and Dammacco, F.
38. The Registry for Insulin-Dependent Diabetes Mellitus in Italy (RIDI) project | Il progetto per il registro italiano del Diabete Mellito insulino-dipendente (RIDI)
- Author
-
Cherubini, V., Carle, F., Iannilli, A., Kantar, A., Coppa, G. V., Chiumello, G., Angius, E., Banin, P., Bellù, L., Berardi, R., Bernasconi, S., Mariani, S., Boscherini, B., Fonte, M. T., Cacciari, E., Salardi, S., Cadario, F., Calisti, Cardella, F., Cavallo, L., Cerasoli, G., Cerutti, F., Chiarelli, F., Verrotti, A., Cicchetti, M., Cotellessa, M., Picco, P., Crino, A., Dammacco, F., Giorgi, G., Luca, F., Falorni, A., Fifi, A., Franzese, A., Gargantini, G., Giorgetti, R., Guazzarotti, L., La Loggia, A., Lorini, R., D Annunzio, G., Lucentini, L., Mannazzu, M. C., Marietti, G., Marsciani, A., Martinucci, M., Mastrangelo, C., Meossi, C., Meschi, F., Monciotti, C., Multari, G., Pinelli, L., Pocecco, M., Prisco, F., Jafusco, D., Reitano, G., Sacchini, P., Sacco, M., Alessandro Salvatoni, Scaramuzza, A., Vanelli, M., Chiari, G., Vanini, R., Visentin, A., and Zanini, R.
39. Early responder myeloma: Kinetic studies identify a patient subgroup characterized by very poor prognosis
- Author
-
Boccadoro, M., Marmont, F., Tribalto, M., Fossati, G., Redoglia, V., Battaglio, S., Massaia, M., Gallamini, A., Comotti, B., Barbui, T., Campobasso, N., Dammacco, F., Maria CANTONETTI, Petrucci, M. T., Mandelli, F., Resegotti, L., and Pileri, A.
- Subjects
Male ,Cancer Research ,Settore MED/06 - Oncologia Medica ,medicine.medical_treatment ,oral drug administration ,Labeling index ,Plasma cell ,Gastroenterology ,vincristine EMTREE medical terms: adult ,Middle Age ,Random Allocation ,EMTREE drug terms: carmustine ,cyclophosphamide ,doxorubicin ,melphalan ,prednisone ,aged ,bone marrow ,female ,human ,intravenous drug administration ,major clinical study ,male ,multiple myeloma ,priority journal ,prognosis ,survival MeSH: Actuarial Analysis ,Aged ,Antineoplastic Combined Chemotherapy Protocols ,Bone Marrow ,Cell Cycle ,Female ,Human ,Multiple Myeloma ,Plasma Cells ,Prognosis ,Remission Induction ,Support, Non-U.S. Gov't ,Actuarial Analysis ,Medicine ,Non-U.S. Gov't ,Multiple myeloma ,Middle Aged ,medicine.anatomical_structure ,Oncology ,Support ,Median survival ,medicine.medical_specialty ,Poor prognosis ,Internal medicine ,Humans ,Chemotherapy ,business.industry ,medicine.disease ,Surgery ,Remission duration ,Bone marrow ,business ,Settore MED/15 - Malattie del Sangue - Abstract
In order to assess the prognostic value of rapid tumor mass reduction in responding multiple myeloma (MM) patients, 100 consecutive patients were analyzed, and bone marrow plasma cell kinetic characteristics were evaluated at diagnosis. Forty-two patients obtained a tumor mass reduction greater than or equal to 50% with three cycles of chemotherapy and within 3 months (early responder myeloma [ERM]), and 23 in greater than 3 months (slow responder myeloma [SRM]). Survival rates in these two groups were not statistically different (P = .07). The labeling index (LI) of bone marrow plasma cells was significantly higher in ERM patients than in SRM patients (1.8 +/- 2.0 v 0.8 +/- 0.7, P = .006). The LI was used to separate the ERM patients into two well-defined subgroups. ERM patients with a LI greater than or equal to 2% showed a median survival of 16.4 months, whereas ERM patients with a LI less than 2% did not reach the median survival at 46.9 months (P less than .0044). Remission duration was also significantly different: 12.2 months in the high LI subgroup and 26.3 months in the low LI subgroup (P less than .0025). Early response itself does not correspond to shorter remission duration and shorter survival, but it is a poor prognostic factor if associated with a high plasma cell proliferative activity.
40. [Anti-idiotypic antibodies in therapy: current status and prospects]
- Author
-
Federico Perosa and Dammacco F
- Subjects
Neoplasms ,Terminology as Topic ,Immunization, Passive ,Humans ,Immunotherapy ,Communicable Diseases ,Antibodies, Anti-Idiotypic ,Autoimmune Diseases
41. Stimulation of residual B-cell immunity in nude mice by pidotimod: An immunohistological study
- Author
-
Vacca, A., Di Stefano, R., gabriella serio, and Dammacco, F.
42. The natural history of cryoglobulinemia: Symptoms at onset and during follow-up. A report by the Italian Group for the Study of Cryoglobulinemias (GISC)
- Author
-
Monti, G., Saccardo, F., Pioltelli, P., Rinaldi, G., Danieli, G., Candela, M., Gabrielli, A., Dammacco, F., Vacca, A., Invernizzi, F., Pietrogrande Renoldi, M. P., MASSIMO GALLI, Colasanti, G., Maldifassi, P., Pinerolo, C., Montoli, F., Mussini, C., and Mascia, M. T.
43. Inhibitory Effect of Cyproheptadine Administration on the Sleep-Related Growth Hormone Secretion in Man
- Author
-
Dammacco F, C Torelli, Candeliere C, Specchio Lm, Fm Puca, Galeone D, Rigillo N, Mastrangelo C, Genco S, and G. Chetri
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,business.industry ,Endocrinology, Diabetes and Metabolism ,Biochemistry (medical) ,Clinical Biochemistry ,Cyproheptadine ,Sleep, REM ,General Medicine ,Biochemistry ,Sleep in non-human animals ,Growth hormone secretion ,Endocrinology ,Growth Hormone ,Internal medicine ,medicine ,Humans ,Sleep ,business ,Inhibitory effect ,medicine.drug - Published
- 1977
44. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study
- Author
-
Paola Tacchetti, Lucia Pantani, Francesca Patriarca, Maria Teresa Petrucci, Elena Zamagni, Luca Dozza, Monica Galli, Francesco Di Raimondo, Claudia Crippa, Mario Boccadoro, Simona Barbato, Patrizia Tosi, Franco Narni, Vittorio Montefusco, Nicoletta Testoni, Antonio Spadano, Carolina Terragna, Norbert Pescosta, Giulia Marzocchi, Claudia Cellini, Piero Galieni, Sonia Ronconi, Marco Gobbi, Lucio Catalano, Antonio Lazzaro, Giovanni De Sabbata, Clotilde Cangialosi, Fabrizio Ciambelli, Pellegrino Musto, Francesca Elice, Michele Cavo, Renato Fanin, Roberto Foa', Alessandro Rambaldi, Giuseppe Rossi, Pietro Leoni, Paolo Corradini, Giuseppe Torelli, Giuseppe Fioritoni, Sergio Cortelazzo, Giorgio Lambertenghi Deliliers, Giorgio La Nasa, Alfonso Zaccaria, Paolo De Fabritiis, Nicola Cascavilla, Alberto Bosi, Gianpietro Semenzato, Luigi Gugliotta, Filippo Gherlinzoni, Emanuele Angelucci, Massimo Fabrizio Martelli, Maria Concetta Petti, Giuseppe Leone, Angelo Michele Carella, Fabio Ciceri, Armando Santoro, Felicetto Ferrara, Francesco Nobile, Alfonso Maria D'Arco, Alessandro Levis, Luciano Guardigni, Andrea Gallamini, Pier Paolo Fattori, Sergio Morandi, Dino Amadori, Bruno Rotoli, Salvatore Mirto, Giorgio Paladini, Ruggero Mozzana, Graziella Pinotti, Francesco Rodeghiero, Nicola Cantore, Vincenzo Pavone, Enrico Maria Pogliani, Anna Marina Liberati, Ignazio Majolino, Sergio Amadori, Francesco Lauria, Massimo Aglietta, Giovanni Quarta, Sergio Storti, Fortunato Morabito, Silvana Franca Capalbo, Alessandro Massimo Gianni, Vincenzo Mettivier, Vittorio Rizzoli, Carlo Bernasconi, Giuseppe Visani, Michele Pizzuti, Giacinto La Verde, Giuseppe Avvisati, Maurizio Longinotti, Eugenio Gallo, Franco Dammacco, Domenico Russo, Andrea Bacigalupo, Caterina Musolino, Tacchetti P., Pantani L., Patriarca F., Petrucci M.T., Zamagni E., Dozza L., Galli M., Di Raimondo F., Crippa C., Boccadoro M., Barbato S., Tosi P., Narni F., Montefusco V., Testoni N., Spadano A., Terragna C., Pescosta N., Marzocchi G., Cellini C., Galieni P., Ronconi S., Gobbi M., Catalano L., Lazzaro A., De Sabbata G., Cangialosi C., Ciambelli F., Musto P., Elice F., Cavo M., Fanin R., Foa' R., Rambaldi A., Rossi G., Leoni P., Corradini P., Torelli G., Fioritoni G., Cortelazzo S., Lambertenghi Deliliers G., La Nasa G., Zaccaria A., De Fabritiis P., Cascavilla N., Bosi A., Semenzato G., Gugliotta L., Gherlinzoni F., Angelucci E., Martelli M.F., Petti M.C., Leone G., Carella A.M., Ciceri F., Santoro A., Ferrara F., Nobile F., D'Arco A.M., Levis A., Guardigni L., Gallamini A., Fattori P.P., Morandi S., Amadori D., Rotoli B., Mirto S., Paladini G., Mozzana R., Pinotti G., Rodeghiero F., Cantore N., Pavone V., Pogliani E.M., Liberati A.M., Majolino I., Amadori S., Lauria F., Aglietta M., Quarta G., Storti S., Morabito F., Capalbo S.F., Gianni A.M., Mettivier V., Rizzoli V., Bernasconi C., Visani G., Pizzuti M., La Verde G., Avvisati G., Longinotti M., Gallo E., Dammacco F., Russo D., Bacigalupo A., and Musolino C.
- Subjects
Adult ,Male ,medicine.medical_specialty ,Transplantation Conditioning ,Adolescent ,Phases of clinical research ,Transplantation, Autologous ,Dexamethasone ,Bortezomib ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,GIMEMA-MMY-3006 trial, bortezomib, thalidomide, dexamethasone, VTD, double autologous haematopoietic stem-cell transplantation, multiple myeloma ,Multiple myeloma ,Aged ,Intention-to-treat analysis ,business.industry ,Hazard ratio ,Hematopoietic Stem Cell Transplantation ,Hematology ,Middle Aged ,medicine.disease ,Thalidomide ,Transplantation ,Regimen ,030220 oncology & carcinogenesis ,Female ,Multiple Myeloma ,business ,Follow-Up Studies ,030215 immunology ,medicine.drug - Abstract
Background: The phase 3 GIMEMA-MMY-3006 trial, which compared bortezomib, thalidomide, and dexamethasone (VTD) combination therapy with thalidomide and dexamethasone (TD) as induction therapy before and consolidation therapy after double autologous haematopoietic stem-cell transplantation (HSCT) for newly diagnosed multiple myeloma, showed the superiority of the triplet regimen over the doublet in terms of increased complete response rate and improved progression-free survival. We report the results from the final analysis of the study. Methods: In this randomised, open-label, phase 3 study, patients aged 18–65 years with previously untreated symptomatic multiple myeloma and a Karnofsky Performance Status of 60% or higher were enrolled at 73 centres in Italy. Patients were randomised (1:1) by a web-based system to receive three 21-day cycles of thalidomide (100 mg daily orally for the first 14 days and 200 mg daily thereafter) plus dexamethasone (total 320 mg per cycle; 40 mg on days 1–2, 4–5, 8–9, and 11–12 in the VTD regimen, and 40 mg on days 1–4 and 9–12 in the TD regimen), either alone (TD group) or with bortezomib (1·3 mg/m2 intravenously on days 1, 4, 8, and 11; VTD group). After double autologous HSCT, patients received two 35-day cycles of either the VTD or TD regimen, according to random assignment, as consolidation therapy. The primary outcome was the rate of complete response and near complete response after induction (already reported). In this updated analysis we assessed long-term progression-free survival and overall survival (secondary endpoints of the study) with an extended 10-year median follow-up, and analysed the variables influencing survival. Analysis was by intention to treat. The study is registered with ClinicalTrials.gov, NCT01134484. Findings: Between May 10, 2006, and April 30, 2008, 480 patients were enrolled and randomly assigned to receive VTD (241 patients) or TD (239 patients). Six patients withdrew consent before start of treatment. 236 (99 [42%] women) in the VTD group and 238 (102 [43%] women) in the TD group were included in the intention-to-treat analysis. The data cutoff date for this analysis was May 31, 2018. Median follow-up for surviving patients was 124·1 months (IQR 117·2–131·7). The 10-year progression-free survival estimate for patients in the VTD group was 34% (95% CI 28–41) compared with 17% (13–23) for the TD group (hazard ratio [HR] 0·62 [95% CI 0·50–0·77]; p
- Published
- 2020
45. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial
- Author
-
Patrizia Falco, Cecilia Rus, Mariella Grasso, Vito Michele Lauta, Maria Teresa Petrucci, Angelo Michele Carella, Martina Nunzi, Antonio Capaldi, Tommaso Caravita, Anna Maria Barbui, Federica Cavallo, Fausto Rossini, Pellegrino Musto, Vincenzo Callea, Alessandra Bertola, Franco Mandelli, Massimo Massaia, Giovannino Ciccone, Mario Boccadoro, Sara Bringhen, Antonio Palumbo, Tommasina Guglielmelli, Franco Dammacco, Anna Marina Liberati, Patrizia Pregno, Cesare Bergonzi, Enrico Pogliani, Palumbo, A, Bringhen, S, Petrucci, M, Musto, P, Rossini, F, Nunzi, M, Lauta, V, Bergonzi, C, Barbui, A, Caravita, T, Capaldi, A, Pregno, P, Guglielmelli, T, Grasso, M, Callea, V, Bertola, A, Cavallo, F, Falco, P, Rus, C, Massaia, M, Mandelli, F, Carella, A, Pogliani, E, Liberati, A, Dammacco, F, Ciccone, G, and Boccadoro, M
- Subjects
Male ,Melphalan ,medicine.medical_treatment ,DIAGNOSED MULTIPLE-MYELOMA ,COMBINATION CHEMOTHERAPY ,Salvage therapy ,THERAPY ,Biochemistry ,Gastroenterology ,MED/15 - MALATTIE DEL SANGUE ,Prednisone ,FINAL ANALYSIS ,Medicine ,Multiple myeloma ,Standard treatment ,Hematology ,Middle Aged ,Chemotherapy regimen ,Treatment Outcome ,STEM-CELL TRANSPLANTATION ,AUTOLOGOUS TRANSPLANTATION ,INTENSIVE MELPHALAN ,TANDEM TRANSPLANTS ,STAGING SYSTEM ,200 MG/M(2) ,Female ,Survival Analysi ,Multiple Myeloma ,Human ,medicine.drug ,medicine.medical_specialty ,Immunology ,Disease-Free Survival ,Follow-Up Studie ,Internal medicine ,Humans ,Antineoplastic Agents, Alkylating ,Aged ,Salvage Therapy ,Chemotherapy ,business.industry ,Cell Biology ,medicine.disease ,Survival Analysis ,Surgery ,Regimen ,business ,Follow-Up Studies - Abstract
High-dose therapy is an effective standard treatment for multiple myeloma patients. Evidence that intermediate-dose therapy improves survival is limited. At diagnosis, about 70% of patients are older than 65. Intermediate-dose regimen is very well tolerated in older patients. In a multicenter study, 194 patients were randomized to receive at diagnosis either conventional chemotherapy (6 courses of oral melphalan and prednisone [MP]) or intermediate-dose therapy (2 courses of melphalan at 100 mg/m(2) [MEL100]) with stem cell support. Response rate was higher after MEL100. Near-complete remission (nCR) was 6% after MP and 25% after MEL100 (P = .0002). At 3 years, MEL100 increased event-free survival (EFS) from 16% to 37% and overall survival (OS) from 62% to 77% (P < .001). Similar results were observed in patients aged 65 to 70: nCR was 8% after MP and 25% after MEL100 (P = .05); at 3 years, MEL100 improved EFS from 18% to 31% (P = .01) and OS from 58% to 73% (P = .01). Patients aged 65 to 70 had a median OS of 37.2 months (MP) versus 58 months (MEL100). Intermediate-dose melphalan improves response rate, EFS, and OS in myeloma patients, specifically in those aged 65 to 70. It constitutes a more effective first-line regimen than standard treatment for elderly patients.
- Published
- 2004
46. Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib
- Author
-
Paola Neri, Antonio Gnoni, Domenico Ribatti, Franco Dammacco, Angelo Vacca, M. C. Colanardi, Pierfrancesco Tassone, Domenica Mangieri, Nicola Di Renzo, Teresa Cirulli, Addolorata Coluccia, Carlo Gambacorti-Passerini, Coluccia, A, Cirulli, T, Neri, P, Mangieri, D, Colanardi, M, Gnoni, A, Di Renzo, N, Dammacco, F, Tassone, P, Ribatti, D, GAMBACORTI PASSERINI, C, and Vacca, A
- Subjects
Adult ,Male ,Platelet-derived growth factor ,medicine.drug_class ,Angiogenesis ,PDGFR beta, c-Src, tyrosine kinases, dasatinib ,medicine.medical_treatment ,Immunology ,Dasatinib ,Drug Evaluation, Preclinical ,Antineoplastic Agents ,Mice, SCID ,Biochemistry ,Tyrosine-kinase inhibitor ,Receptor, Platelet-Derived Growth Factor beta ,chemistry.chemical_compound ,Mice ,Drug Delivery Systems ,medicine ,Tumor Cells, Cultured ,Animals ,Humans ,Protein Kinase Inhibitors ,Aged ,biology ,business.industry ,Growth factor ,Cell Biology ,Hematology ,Middle Aged ,Xenograft Model Antitumor Assays ,Vascular endothelial growth factor ,Vascular endothelial growth factor A ,Thiazoles ,Pyrimidines ,src-Family Kinases ,chemistry ,Cancer research ,biology.protein ,Female ,business ,Multiple Myeloma ,Platelet-derived growth factor receptor ,medicine.drug - Abstract
Inhibition of multiple myeloma (MM) plasma cells in their permissive bone marrow microenvironment represents an attractive strategy for blocking the tumor/vessel growth associated with the disease progression. However, target specificity is an essential aim of this approach. Here, we identified platelet-derived growth factor (PDGF)–receptor beta (PDGFRβ) and pp60c-Src as shared constitutively activated tyrosine-kinases (TKs) in plasma cells and endothelial cells (ECs) isolated from MM patients (MMECs). Our cellular and molecular dissection showed that the PDGF-BB/PDGFRβ kinase axis promoted MM tumor growth and vessel sprouting by activating ERK1/2, AKT, and the transcription of MMEC-released proangiogenic factors, such as vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8). Interestingly, pp60c-Src TK-activity was selectively induced by VEGF in MM tumor and ECs, and the use of small-interfering (si)RNAs validated pp60c-Src as a key signaling effector of VEGF loop required for MMEC survival, migration, and angiogenesis. We also assessed the antitumor/vessel activity of dasatinib, a novel orally bioactive PDGFRβ/Src TK-inhibitor that significantly delayed MM tumor growth and angiogenesis in vivo, showing a synergistic cytotoxicity with conventional and novel antimyeloma drugs (ie, melphalan, prednisone, bor-tezomib, and thalidomide). Overall data highlight the biologic and therapeutic relevance of the combined targeting of PDGFRβ/c-Src TKs in MM, providing a framework for future clinical trials.
- Published
- 2008
47. Modulation of the Fcgamma receptors induced by anti-Ro and anti-La autoantibodies: observations in salivary gland cells
- Author
-
Margherita Sisto, F. Dammacco, Dario Domenico Lofrumento, Vincenzo Mitolo, Massimo D'Amore, P. Scagliusi, Sabrina Lisi, Maria Antonia Frassanito, Lisi, S, D'Amore, M, Lofrumento, Dario Domenico, Mitolo, V, Frassanito, Ma, Dammacco, F, Scagliusi, P, and Sisto, M.
- Subjects
Male ,Fc gamma receptor ,Immunology ,Biology ,Autoantigens ,Salivary Glands ,Flow cytometry ,Cell Line ,Sepharose ,Rheumatology ,Downregulation and upregulation ,Upregulation ,Autoimmune disease ,medicine ,Immunology and Allergy ,Humans ,Receptor ,Salivary gland ,medicine.diagnostic_test ,Receptors, IgG ,Autoantibody ,Middle Aged ,medicine.disease ,Autoantibodie ,Up-Regulation ,medicine.anatomical_structure ,Sjogren's Syndrome ,Ribonucleoproteins ,Antibodies, Antinuclear ,Case-Control Studies ,Sjogren’s syndrome ,Female ,Anti-SSA/Ro autoantibodies - Abstract
Only few reports have shown protein expression of the Fcgamma receptors (FcgammaRs) molecules on human salivary gland cells. In this study we investigate a possible upregulation of FcgammaRs following anti-Ro and anti-La autoantibodies treatment. Anti-Ro and anti-La autoantibodies were purified from IgG fractions obtained from 14 patients with primary Sjögren's syndrome (SS), using Sepharose 4B-Ro and Sepharose 4B-La affinity columns. Flow cytometry and RT-PCR were used to study the FCgammaRI, FCgammaRII and FCgammaRIII receptors expression and upregulation by anti-Ro and anti-La on a salivary gland cell line. The present data document that the anti-Ro and anti-La autoantibodies determine an increase of the FcgammaRs expression on salivary gland cells, and provide evidence that both the high affinity FcgammaRI and the low affinity FcgammaRII and FcgammaRIII are overexpressed. Treatment with IgG isolated from healthy donors had no effect on the basal FCgammaRs expression.
- Published
- 2007
48. HCV-NS3 and IgG-Fc crossreactive IgM in patients with type II mixed cryoglobulinemia and B-cell clonal proliferations
- Author
-
Domenico Sansonno, F. Dammacco, Vito Racanelli, Laura Caggiari, Silvano Geremia, Felicia Anna Tucci, V. De Re, Renato Talamini, Martina Fabris, Daniela Gasparotto, Mara Campagnolo, S. De Vita, Maria Paola Simula, DE RE, V, Sansonno, D, SIMULA M., P, Caggiari, L, Gasparotto, D, Fabris, M, TUCCI F., A, Racanelli, V, Talamini, R, Campagnolo, M, Geremia, Silvano, Dammacco, F, and DE VITA, S.
- Subjects
Models, Molecular ,Cancer Research ,Lymphoma, B-Cell ,Protein Conformation ,viruses ,Population ,Receptors, Antigen, B-Cell ,Biology ,Viral Nonstructural Proteins ,Epitope ,Protein Structure, Secondary ,Epitopes ,Antigen ,Rheumatoid Factor ,medicine ,Rheumatoid factor ,Humans ,education ,B cell ,education.field_of_study ,virus diseases ,Hematology ,medicine.disease ,Virology ,Cryoglobulinemia ,Peptide Fragments ,Clone Cells ,Immunoglobulin Fc Fragments ,medicine.anatomical_structure ,Oncology ,Immunoglobulin M ,Polyclonal antibodies ,biology.protein ,Protein Binding - Abstract
We demonstrate that in three cases of MC (two with immunocytoma), the IgM-RF+ component of their cryoprecipitated represents the circulating counterpart of the B-cell receptor (BCR) of the monoclonal overexpanded B-cell population. These IgMs were isolated and used to demonstrate a crossreactivity against both hepatitis C virus (HCV) NS3 antigen and the Fc portion of IgG. Epitopes were identified in a fraction of exemplary samples by using epitope excision approach (NS(31250-1334) and IgG Fc(345-355)). The same phenomenon of crossreactivity has been shown to occur in vivo after immunization of a mouse with the NS3(1251-1270) peptide. To verify if the same reaction was also present in MC samples characterized by an oligo/polyclonal B-cell proliferation, IgM crossreactivity was tested in 14 additional samples. Five out of the 14 were reactive against HCV NS3 and 11 out of 14 were reactive against IgG-Fc peptide. The data support the role of HCV NS3 antigen in a subset of patients with MC, whereas the high frequency of the IgG-Fc epitope suggests that these B cells originate from precursors strongly selected for auto-IgG specificity. We suggest that engagement of specific BCRs by NS3 (or NS3-immunocomplex) antigen could explain the prevalence of IgM cryoglobulins in these patients.
- Published
- 2006
49. CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group
- Author
-
F. De Vita, Vito Lorusso, F. Dammacco, M. De Lena, G Mantovani, V M Lauta, F. Marzullo, G Polimeno, M. D'Aprile, Giovannella Palmieri, Giuseppina Catalano, Ar Bianco, Giuseppe Lucarelli, G Abate, Lorusso, V, Palmieri, G, Bianco, Ar, Abate, G, Catalano, G, DE VITA, Ferdinando, Dammacco, F, Lauta, Vm, Lucarelli, G, Polimeno, G, Mantovani, G, D'Aprile, M, Marzullo, F, and DE LENA, M.
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Gastroenterology ,Bleomycin ,International Prognostic Index ,Prednisone ,Multicenter trial ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Cyclophosphamide ,Survival analysis ,Aged ,Epirubicin ,Etoposide ,Neoplasm Staging ,Intention-to-treat analysis ,business.industry ,Lymphoma, Non-Hodgkin ,Cytarabine ,Middle Aged ,medicine.disease ,Survival Analysis ,Surgery ,Non-Hodgkin's lymphoma ,Lymphoma ,Regimen ,Methotrexate ,Treatment Outcome ,Oncology ,Doxorubicin ,Vincristine ,Female ,business ,medicine.drug - Abstract
From January 1992 to December 1995, 129 patients with previously untreated non-Hodgkin's lymphoma were randomised in a phase III multicenter trial to receive CEOP-B/VIMB or ProMACE-CytaBOM. Eligibility criteria included intermediate or high grade lymphoma (follicular large cell, diffuse small cleaved-cell, diffuse mixed, diffuse large-cell and immunoblastic) with an Ann Arbor stage II bulky, III or IV. All patients entered into the study were considered evaluable according to intent to treat analysis. At a median follow-up of 60 months there were no significant differences between the treatment response rates [82% (60%CR) for CEOP-B/VIMB vs. 81% (69% CR) for ProMACE-CytaBOM]. Conversely, with regard to disease-free survival, a significant difference was observed between the two treatment arms (42% for CEOP-B/VIMB vs. 24% for ProMACE-CytaBOM at 5 years; p=0.046). However, this difference did not translate in a significant difference in overall survival (45% vs. 39% at 5 years). Moreover, when response rates and outcome were analysed for different prognostic subgroups according to International Prognostic Index, no significant differences were observed between the treatment groups. It is important to note that neither regimen was able to improve outcome of poor risk patients who fared badly with both treatments (median survival 9 and 8 months respectively). Toxicity was also similar in both treatments with grade 3-4 leukopenia observed in 39% and 47% of cases and grade 3-4 thrombocytopenia in 24% and 27% of cases respectively. In conclusion, in this study CEOP-B/VIMB was not superior to ProMACE-CytaBOM in aggressive lymphomas and the alternating strategy failed to improve outcome of poor risk patients in which newer more aggressive treatments are needed.
- Published
- 2000
50. Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis
- Author
-
Marcella Prete, Liboria Digiglio, Giovanna Cuomo, Franco Dammacco, Vito Racanelli, Elvira Favoino, Gabriele Valentini, Federico Perosa, Perosa, F, Favoino, E, Cuomo, Giovanna, Digiglio, L, Dammacco, F, Prete, M, Valentini, Gabriele, and Racanelli, V.
- Subjects
Adult ,Male ,medicine.medical_specialty ,Chromosomal Proteins, Non-Histone ,Immunology ,Enzyme-Linked Immunosorbent Assay ,disease activity index ,Cross Reactions ,Autoantigens ,Epitope ,symbols.namesake ,Rheumatology ,Scleroderma, Limited ,Internal medicine ,Humans ,Immunology and Allergy ,Medicine ,In patient ,skin and connective tissue diseases ,Fisher's exact test ,Autoantibodies ,Retrospective Studies ,Scleroderma, Systemic ,integumentary system ,biology ,Receiver operating characteristic ,Immunodominant Epitopes ,business.industry ,Autoantibody ,Forkhead Transcription Factors ,FOXE-3 ,peptide ,ROC Curve ,biology.protein ,symbols ,Systemic sclerosis ,Female ,Antibody ,business ,CENP-A ,Biomarkers ,Centromere Protein A ,Research Article - Abstract
INTRODUCTION: In a subset of patients with limited cutaneous (lc) systemic sclerosis (SSc), anti-CENP-A antibodies (Ab) cross-react with a peptide (FOXE3p53-62) that presents striking homology with one of the two immunodominant epitopes of CENP-A (Ap17-30). We searched for clinical correlates of anti-FOXE3p53-62 Ab by measuring their levels along with those of Ab to Ap17-30 and to the second immunodominant epitope of CENP-A, namely Ap1-17. METHODS: Serum samples were obtained from 121 patients with SSc, 46 patients with systemic lupus erythematosus (SLE) and 25 healthy blood donors (HBD). The reactivity of serum IgG to Ap1-17, Ap17-30 and FOXE3p53-62 was measured by ELISA. The corresponding anti-peptide Ab were affinity-purified from pooled SSc sera and used to establish standard curves for quantifying these Ab in patients and HBD. Receiver operating characteristics (ROC) analysis, comparing SSc patients who were positive for anti-CENP Ab (ACA+) to those who were negative, was used to find cut-off points for dichotomizing the anti-peptide Ab levels into positive and negative. Clinical records were reviewed to extract demographic data and information about organ involvement and disease activity. RESULTS: Of 121 SSc sera, 75 were ACA+; 88.0% of these samples reacted with Ap1-17, 82.6% with Ap17-30 and 53.3% with FOXE3p53-62. Among the 46 ACA- SSc sera, 2.2% reacted with Ap1-17, 4.3% with Ap17-30 and 11% with FOXE3p53-62. The levels of these Ab were low in ACA-, SLE and HBD groups and not significantly different among them. When ACA+ SSc patients were divided into subgroups positive or negative for anti-FOXE3p53-62 Ab, the only variables that were significantly different between groups were the levels of anti-Ap17-30 Ab and disease activity index (DAI). There was a significant association between negativity for anti-FOXE3p53-62 Ab and active disease defined as either DAI ≥3 (Fisher exact test, P = 0.045) or less restrictive DAI≥2.5 (P = 0.009). CONCLUSIONS: ACA+-Anti-FOXE3p53-62+Ab identifies a subgroup of patients with lcSSc who are less likely to develop active disease. In lc SSc patients at presentation, anti-FOXE3p53-62+ can be a marker with prognostic significance.
- Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.